Amanote Research
Register
Sign In
New Frontiers in Cardiovascular Risk Reduction: People With Diabetes and Dyslipidaemia
Diabetes, Obesity and Metabolism
- United Kingdom
doi 10.1111/dom.13742
Full Text
Open PDF
Abstract
Available in
full text
Categories
Internal Medicine
Endocrinology
Metabolism
Diabetes
Date
April 1, 2019
Authors
Unknown
Publisher
Wiley
Related search
Residual Cardiovascular Risk Among People With Diabetes
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
Prevalence of Dyslipidaemia and Pre-Diabetes Among Women With Polycystic Ovary Syndrome (PCOS): Do We Overestimate Cardiovascular Risk?
Hormone and Metabolic Research
Biochemistry
Endocrinology
Clinical Biochemistry
Medicine
Metabolism
Diabetes
Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors in People With Diabetes and Dyslipidaemia
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
Diet, Smoking and Cardiovascular Risk in People With Schizophrenia
British Journal of Psychiatry
Medicine
Psychiatry
Mental Health
Does Cardiovascular Risk Reduction Alleviate Erectile Dysfunction in Men With Type II Diabetes Mellitus?
International Journal of Impotence Research
Urology
From Weight Management via Diabetes Control to Cardiovascular Risk Reduction
Advances in Obesity, Weight Management & Control
Cardiovascular Risk Factor Burden in U.S. People With Incident Type 2 Diabetes Receiving Antidiabetic and Cardioprotective Therapies
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
The New Frontiers of Rehabilitation Medicine in People With Chronic Disabling Illnesses
European Journal of Internal Medicine
Internal Medicine
